SOADOR
BCRX icon

State of Alaska Department of Revenue’s BioCryst Pharmaceuticals BCRX Stock Holding History

State of Alaska Department of Revenue’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$118K Hold
11,899
– – ﹤0.01% 1739
2026
Q1 		$113K Hold
11,899
– – ﹤0.01% 1742
2025
Q4 		$92K Hold
11,899
– – ﹤0.01% 1792
2025
Q3 		$90K Buy
+11,899
New +$99.1K ﹤0.01% 1691

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

State of Alaska Department of Revenue's BCRX Position: Q2 2026 in Review

State of Alaska Department of Revenue held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 11,899 shares worth $118K. The position accounts for ﹤0.01% of the portfolio, ranked #1739.

State of Alaska Department of Revenue first reported a position in BCRX in Q3 2025 and has held it in 4 quarters since. 183 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • State of Alaska Department of Revenue held 11,899 shares of BioCryst Pharmaceuticals worth $118K as of Q2 2026.
  • State of Alaska Department of Revenue left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of State of Alaska Department of Revenue's portfolio in Q2 2026, its #1739 holding.
  • State of Alaska Department of Revenue first reported a position in BioCryst Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 183 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on State of Alaska Department of Revenue's 13F filing for Q2 2026, filed 20 Jul 2026.